Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab and Nab-Paclitaxel in Advanced NSCLC
NCT02733250Phase 2Completed
- Sponsor
- Centre hospitalier de l’Université de Montréal
- Start
- Mar 2017
- Primary completion
- Apr 2019
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab, paclitaxel in non-small cell lung cancer (NSCLC), sponsored by Centre hospitalier de l’Université de Montréal. Started Mar 2017; status: completed.
02
Drugs
pembrolizumabpaclitaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02733250.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02733250.